EphA3 Antibody (4-RE49): sc-134330
- EphA3 Antibody (4-RE49) is a mouse monoclonal IgG1 κ provided at 100 µg/ml
- raised against recombinant EphA3 protein of human origin
- recommended for detection of EphA3 of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for EphA3 Antibody (4-RE49). This work is in progress.
EphA3 Antibody (4-RE49) is a mouse monoclonal IgG1 antibody that detects EphA3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). EphA3 is a member of the Eph receptor family, which represents the largest group of receptor protein tyrosine kinases identified to date, playing a crucial role in various biological processes, particularly in the central nervous system and during development. EphA3 is primarily located on the cell surface, where EphA3 interacts with ephrin-A4 and ephrin-B2 ligands to mediate cell signaling pathways that influence cell positioning, migration, and adhesion. This spatial regulation is vital for proper neuronal development and tissue organization, as aberrations in EphA3 signaling have been implicated in various neurological disorders and cancers. Anti-EphA3 antibody (4-RE49) is an essential tool for researchers aiming to explore the functional dynamics of EphA3 in both physiological and pathological contexts, providing insights into its role in cellular communication and development.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EphA3 Antibody (4-RE49) References:
- EphA3, induced by PC-1/PrLZ, contributes to the malignant progression of prostate cancer. | Wu, R., et al. 2014. Oncol Rep. 32: 2657-65. PMID: 25231727
- Epha3 acts as proangiogenic factor in multiple myeloma. | Caivano, A., et al. 2017. Oncotarget. 8: 34298-34309. PMID: 28415715
- Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1. | Diao, X., et al. 2018. Oncol Rep. 40: 1174-1184. PMID: 29917167
- EphA3 Downregulation by Hypermethylation Associated with Lymph Node Metastasis and TNM Stage in Colorectal Cancer. | Wang, Y., et al. 2019. Dig Dis Sci. 64: 1514-1522. PMID: 30560328
- Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics. | London, M. and Gallo, E. 2020. Mol Biol Rep. 47: 5523-5533. PMID: 32621117
- EphA3 deficiency in the hypothalamus promotes high-fat diet-induced obesity in mice. | Zhang, J., et al. 2022. J Biomed Res. 37: 179-193. PMID: 37013864
- The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. | Talia, M., et al. 2023. J Exp Clin Cancer Res. 42: 164. PMID: 37434266
- Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression. | Vail, ME., et al. 2023. Cancers (Basel). 15: PMID: 37760615
- EphA3 CAR T cells are effective against glioblastoma in preclinical models. | Martins, P., et al. 2024. J Immunother Cancer. 12: PMID: 39111832
- EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. | Lertsumitkul, L., et al. 2024. J Immunother Cancer. 12: PMID: 39111833
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EphA3 Antibody (4-RE49) | sc-134330 | 100 µg/ml | $339.00 |